chlorambucil


Also found in: Thesaurus, Medical, Wikipedia.

chlorambucil

(klɔːˈræmbjʊsɪl)
n
(Pharmacology) an alkylating drug derived from nitrogen mustard, administered orally in the treatment of leukaemia and other malignant diseases. Formula: C14H19Cl2NO2
Collins English Dictionary – Complete and Unabridged, 12th Edition 2014 © HarperCollins Publishers 1991, 1994, 1998, 2000, 2003, 2006, 2007, 2009, 2011, 2014
ThesaurusAntonymsRelated WordsSynonymsLegend:
Noun1.chlorambucil - an alkalating agent (trade name Leukeran) used to treat some kinds of cancer
Leukeran
alkylating agent - an antineoplastic drug used to treat some forms of cancer
Based on WordNet 3.0, Farlex clipart collection. © 2003-2012 Princeton University, Farlex Inc.
Translations

chlorambucil

n. clorambucil, forma de mostaza nitrogenada usada para combatir algunas formas de cáncer.
English-Spanish Medical Dictionary © Farlex 2012

chlorambucil

n clorambucilo
English-Spanish/Spanish-English Medical Dictionary Copyright © 2006 by The McGraw-Hill Companies, Inc. All rights reserved.
Mentioned in ?
References in periodicals archive ?
chlorambucil in combination with obinutuzumab in previously-untreated patients with CLL.
Calquence Granted US Breakthrough Therapy Designation for Chronic Lymphocytic Leukemia
The primary endpoint is progression-free survival (PFS) in the CALQUENCE and obinutuzumab arm compared to the chlorambucil and obinutuzumab arm, assessed by an independent review committee (IRC), and a key secondary endpoint is IRC-assessed PFS in the CALQUENCE monotherapy arm compared to the chlorambucil and obinutuzumab arm.
AstraZeneca - CALQUENCE granted US Breakthrough Therapy Designation for chronic lymphocytic leukemia
Elevate CLL TN: Study of Obinutuzumab + Chlorambucil, Acalabrutinib (ACP-196) + Obinutuzumab, and Acalabrutinib in Subjects With Previously Untreated CLL.
Calquence granted US Breakthrough Therapy Designation for chronic lymphocytic leukaemia
The second data set--results from the RESONATE-2 study (PCYC-1115/1116) at a median follow-up of five years --demonstrated durable PFS with IMBRUVICA monotherapy (estimate of 70 percent) versus chlorambucil (estimate of 12 percent) in patients with previously untreated CLL/SLL, including those with genomic high-risk disease.
Johnson & Johnson (NYSE: JNJ) - IMBRUVICA[R] (ibrutinib) Long-Term Data from Two Pivotal Phase 3 Studies at ASCO and EHA Demonstrate Sustained Efficacy and Safety in Patients with Chronic Lymphocytic Leukemia (CLL) -- 3/6/2019
The trial met its primary endpoint; Calquence in combination with obinutuzumab demonstrated a statistically-significant and clinically-meaningful improvement in progression-free survival (PFS) when compared with the chemotherapy-based combination of chlorambucil and obinutuzumab.
AstraZeneca - Calquence Phase III ELEVATE-TN trial met primary endpoint at interim analysis in previously-untreated chronic lymphocytic leukaemia -- 6/6/2019
The primary endpoint is that the combination registered a statistically-significant improvement in progression-free survival during the trial, as compared to the chemotherapy-based combination of chlorambucil and obinutuzumab.
AstraZeneca's Calquence succeeds in phase three ELEVATE-TN trial
According to the company, this trial met its primary endpoint of Calquence in combination with obinutuzumab demonstrating a statistically-significant and clinically-meaningful improvement in progression-free survival (PFS) when compared with the chemotherapy-based combination of chlorambucil and obinutuzumab.
AstraZeneca reports meeting of primary end point by Calquence phase III ELEVATE-TN trial
The primary endpoint was the demonstration of "statistically-significant and clinically-meaningful" improvement in progression-free survival from the combination of Calquence and obinutuzumab against chemotherapy-based treatment of chlorambucil and obinutuzumab.
TOP NEWS SUMMARY: Rolls-Royce And L&G Agree GBP4 Billion Pensions Deal
The trial met its primary endpoint; Calquence in combination with obinutuzumab demonstrated a statistically-significant and clinically-meaningful improvement in progression-free survival when compared with the chemotherapy-based combination of chlorambucil and obinutuzumab.
AstraZeneca says Calquence Phase 3 ELEVATE-TN trial met primary endpoint
Hence, standard chemotherapy agents, such as chlorambucil, bendamustine, cladribine or fludarabine, etc., are not prescribed as first line therapy as they may affect the stem cells.
NavigaWaldenstrom Macroglobulinemia Market Prospects and Growth Assessment Presented Until the End o
Ultimately, the patient was only responsive to the chemotherapy agent chlorambucil (23).
The use of hyperbaric oxygen therapy in the treatment of necrotizing soft tissue infections, compromised grafts and flaps, hidradenitis suppurativa, and pyoderma gangrenosum

Dictionary browser ?
Full browser ?